Sovaldi (Sofosbuvir) – Hepatitis C Treatment

Approved by the FDA in late 2013 and by the EMA in early 2014 Sovaldi (Sofosbuvir) has revolutionized [[hepatitis C treatment]]. The nucleotide polymerase inhibitor is used in cases of chronic viral hepatitis C. This type of treatment does not require Interferon, which is known to cause significant side effects and cause CNS, cardiovascular system, gastro-intestinal tract and hematological symptoms. The inhibitor is used in combination with other antiviral agents and is intended for adults only. It is not available as a monotherapy.

Hepatitis C Treatment

Hepatitis C treatment is performed with a combination of antivirals. Exact treatment depends on the virus’ genotype. Up until recently Interferon was the main ingredient in all protocols. However, due to the severity of the side-effects many patients could not complete the treatment. Additionally, some virus genotypes did not respond to Interferon. As a result, only about 45% of hepatitis C cases ended up being cured. While recent developments slowly increase the cured percentage, it was only with the appearance of Sofosbuvir that it shot up to 97%.

Sovaldi (Sofosbuvir) – Information

Sovaldi (Sofosbuvir) should not be taken during pregnancy or if you're breastfeeding. It is advised to wait for at least 6 months following completion of treatment before attempting to get pregnant. It is important to notify your treating physician of any concomitant conditions you have (such as non-hepatitis-related liver disorders, kidney disease or HIV) and about any other medicines (including vitamins and herbal remedies) you are taking before starting the treatment.